Search
Luliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalLuliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. … It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 CYP3A InhibitorsHyaluronidase
go.drugbank.com/drugs/DB14740ApprovedInvestigational[A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] … Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.
Products: HYLASE® DESSAU 150 IU, HYALASE POWDER FOR INJECTION 1500 iu/ampouleNischarin
go.drugbank.com/bio_entities/BE0003580TargetHumansActs either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell surv...
Synonyms: I-1, I-1 receptor candidate proteinCoal tar
go.drugbank.com/drugs/DB11082ApprovedCoal tar is a brown or black liquid of extremely high viscosity. Coal tar is among the by-products when coal is carbonized to make coke or gasified to make coal gas. … It has been indicated for local relief of itching, dryness, and irritation caused by psoriasis, seborrhea and eczema.
Mixtures: Medi-dan Shampoo, COCOIS CO. OINTMENTProducts: COAL TAR SOLUTION 5% IN AQUEOUS CREAM, Psoriasin In-Shower TreatmentRemdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigationalLike other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. … [L18438] Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc.[L18438] Remdesivir was also approved by the European Commission on July 3, 2020.
Categories: MATE 1 Inhibitors, P-glycoprotein substratesProducts: VEKLURY® LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIAL, VEKLURY 100 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADETCoagulation factor X human
go.drugbank.com/drugs/DB13148ApprovedInvestigationalInherited factor X deficiency is a rare autosomal recessive bleeding disorder that is estimated to occur in 1:1 000 000 individuals up to 1:500 carriers [A31471]. … Coagulation Factor X (Human), is a plasma-derived human blood coagulation factor is used by adults and children (aged 12 years and above) with hereditary Factor X deficiency.
Mixtures: Beriplex P/n 500, Beriplex P/n 1000Categories: Factor X, Factor X, agonistsGuanoxan
go.drugbank.com/drugs/DB13211ApprovedGuanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.
Afatinib
go.drugbank.com/drugs/DB08916ApprovedInvestigationalby an FDA-approved test [L2939]. … For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: GIOTRIF® 30 MG, GIOTRIF® 40 MGEthinamate
go.drugbank.com/drugs/DB01031ApprovedIllicitWithdrawnStructurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates … Like many such similar medications, the regular use of ethinamate can result in the development of drug tolerance in a patient.
Synonyms: 1-ethynylcyclohexanol carbamateDatopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.
Categories: Topoisomerase I Inhibitors, MATE 2 Substrates